What Snooki's Story Can Teach Us About Cervical Cancer and Pap Tests

What she said

In February 2026, Nicole "Snooki" Polizzi told her audience about her diagnosis. It was stage 1 cervical cancer, of the type called adenocarcinoma. "Obviously not the news that I was hoping for," she said, "but also not the worst news just because they caught it so early." She added that "it's only stage 1 and it's curable."

She said she had been dealing with abnormal Pap smears for three or four years, and she turned the announcement into a direct message. "I'm literally telling you guys to get your pap smears done. I'm 38 years old ... and now look at me."

CBS News reported that she had a cone biopsy. That procedure removes a cone of cervical tissue for examination. She also had a PET scan scheduled.

Those are her disclosures, in her words. This article does not go past them. It makes no claim about how her case will unfold. What follows is the medicine behind a cervical cancer diagnosis.

Where this cancer starts

The cervix is the lower end of the uterus. It is a cylinder of fibrous tissue, about 3 to 4 cm long, that opens into the vagina.

It is lined by two different kinds of cell. Squamous cells cover the outer surface. Glandular cells line the endocervical canal running up the middle. Cervical cancer usually begins where those two meet. That boundary is called the squamocolumnar junction, and either cell type can be involved.

Squamous cell carcinoma is the more common form. Adenocarcinoma starts in the gland cells of the canal. NCI notes that this type begins inside the endocervical canal. That makes it harder to remove fully with a cone biopsy than a lesion on the outer surface.

Almost all of it traces to one cause. NCI names human papillomavirus infection as the primary risk factor for cervical cancer.

Why the timeline makes screening work

Cervical cancer does not usually appear from nothing. First comes dysplasia, meaning abnormal cells that are not yet cancer. Doctors call the squamous version cervical intraepithelial neoplasia, or CIN, and the glandular version adenocarcinoma in situ.

That stage can last a long time. NCI reports a figure for untreated in situ cervical cancer. Between 30 and 70 percent of those patients go on to develop invasive cancer, over 10 to 12 years.

But the timeline is not uniform, and this is the part that matters for anyone tempted to postpone. NCI notes that in about 10 percent of patients, lesions progress from in situ to invasive in less than a year.

NCI's health-professional summary states the consequence directly. Most cervical cancers are preventable, through routine screening and treatment of precancerous lesions. Most cases are diagnosed in women living where screening is inadequate.

The screening schedule

The US Preventive Services Task Force gives cervical cancer screening a grade A recommendation for women aged 21 to 65.

• Ages 21 to 29: cervical cytology, meaning a Pap test, every three years.
• Ages 30 to 65: a Pap test every three years, or a high-risk HPV test alone every five years, or both together, called cotesting, every five years.

It recommends against screening women under 21. It also advises against screening after a hysterectomy that removed the cervix, in someone with no history of a high-grade lesion.

The Task Force is also candid about the harms. Many precancerous lesions clear up on their own. Treating those that would never have caused trouble is overdiagnosis. The Task Force notes that cold-knife conization and loop excision are linked to later pregnancy problems, including preterm delivery. That is why follow-up of an abnormal result is a graded process, not an automatic operation.

When to get checked

Screening is the main answer, on the schedule above, whether or not anything feels wrong. NCI is explicit on the reason. Early cervical cancer usually causes no symptoms, and symptoms generally begin after it has spread.

When symptoms do appear, NCI lists these, and advises seeing a health professional rather than waiting:

• Vaginal bleeding after sex.
• Vaginal bleeding after menopause.
• Bleeding between periods, or periods heavier or longer than normal.
• Watery vaginal discharge with a strong odor, or discharge containing blood.
• Pelvic pain, or pain during sex.

With more advanced disease NCI adds painful bowel movements or rectal bleeding, painful urination or blood in the urine, a dull backache, leg swelling, abdominal pain, and fatigue.

Two more points belong here. An abnormal Pap or HPV result needs the follow-up appointment that comes with it. Waiting and seeing is not the plan. The HPV vaccine works earlier still. It prevents infection with the virus types behind most of these cancers.

What treatment involves

Options follow the stage, and NCI lists them in order.

For in situ disease, meaning cancer confined to the surface layer, the main option is conization. It can be done with a scalpel, with a heated wire loop known as LEEP, or with a laser. Hysterectomy is an option for people past childbearing. Internal radiation is an option for those who cannot have surgery. NCI notes that hysterectomy is standard for adenocarcinoma in situ. Conization may be offered to selected patients who want to preserve fertility.

For stage IA, NCI lists conization and total hysterectomy. It also lists modified radical hysterectomy with lymph node removal, and intracavitary radiation. A further option is radical trachelectomy, which removes the cervix but leaves the uterus.

For stages IB and IIA, one option is radiation with chemotherapy at the same time. Another is radical hysterectomy with pelvic lymph node removal, with or without radiation and chemotherapy. NCI also lists radical trachelectomy, radiation alone, and immunotherapy.

For stages IIB through IVA, the mainstay is radiation with chemotherapy at the same time. Interstitial brachytherapy is sometimes added. For stage IVB and recurrent disease, NCI lists immunotherapy, radiation and chemotherapy, palliative systemic therapy, and pelvic exenteration.

The numbers

For 2026 the American Cancer Society projects 13,490 new cervical cancers in the United States and about 4,200 deaths; SEER reprints both counts. SEER's own records put the median age at diagnosis at 50, and the disease is most often diagnosed between 35 and 44.

Five-year relative survival is 68.8 percent across all stages, for women diagnosed between 2016 and 2022. By stage it is 91.8 percent for localized disease. It is 64.0 percent for regional spread, and 20.5 percent when the cancer has reached distant sites. About 41 percent are localized at diagnosis.

Those are group figures, drawn from thousands of women with different tumor types, ages, and treatments. They describe a population, not a person. They say nothing about any individual reader, or about anyone whose story prompted this page.

Sources

• https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq
• https://www.cancer.gov/types/cervical/symptoms
• https://seer.cancer.gov/statfacts/html/cervix.html
• https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
• https://www.cbsnews.com/news/jersey-shore-nicole-snooki-polizzi-cervical-cancer/
• https://www.nbcnews.com/pop-culture/celebrity/nicole-snooki-polizzi-says-diagnosed-stage-1-cervical-cancer-rcna260015